Durvalumab Plus Chemo Showed Continued Survival Benefit in Extensive-Stage SCLC
Updated results from the phase 3 CASPIAN study further established first-line durvalumab with platinum-etoposide as a standard of care for ES-SCLC.
Lung Cancer
Adding Immunotherapy to Chemo Improves Survival in Metastatic Non-Small Cell Lung Cancer
The combinations conferred benefits in nonsquamous non-small cell lung cancer only.
Sugemalimab Deemed Effective as Consolidation for Stage III Non-Small Cell Lung Cancer
Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
Brigatinib Continues to Best Crizotinib in ALK+ Non-Small Cell Lung Cancer
There was an improvement in progression-free survival despite crossover.
Exkivity Approved for EGFR Exon 20 Insertion+ NSCLC
Exkivity (mobocertinib) is approved to treat adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
Study Reveals Shorter Time to Lung Cancer Treatment During COVID-19 Pandemic
The time from cytohistological diagnosis to treatment initiation was longer in 2019 than in 2020.
Lung Cancer Patients Have Lower Antibody Response to COVID-19 Vaccination
Researchers are evaluating whether specific anticancer therapies affect antibody levels.
Type of Surgery and Surgical Pathway Tied to Risk of Perioperative COVID-19 in Non-Small Cell Lung Cancer
Perioperative COVID-19 was associated with a 30-day mortality rate of 26%.
Tumor Microenvironment Predicts Efficacy of PD-1/PD-L1 Blockade in Non-Small Cell Lung Cancer
Response and survival outcomes differed according to the tumor microenvironment.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...